Prosecution Insights
Last updated: May 29, 2026

Genmont Biotech Incorporation

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

2
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (50%)
0
Easy (0%)
1
Unknown (50%)

Rejection Statute Mix

BucketCases
§103 only1 (50%)
No statute on record1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
DAVIS, RUTH A 1 60.6% +31.1%
DURYEE, ALEXANDER MARSH 1 31.8% +40.0%

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18791967 USE OF NUCLEOTIDE OF LACTOBACILLUS FERMENTUM GM-090 FOR PREPARING PHARMACEUTICAL COMPOSITION FOR REGULATING IMMUNITY DAVIS, RUTH A 78d overdue
17862766 COMPOSITION WITH LACTOBACILLUS PARACASEI AND A METHOD TO TREAT NASOPHARYNGEAL CARCINOMA THROUGH PYROPTOSIS OR CELL CYCLE ARREST DURYEE, ALEXANDER MARSH 37d overdue

Top Art Units

Art UnitApps
1699 1
1657 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18791967 USE OF NUCLEOTIDE OF LACTOBACILLUS FERMENTUM GM-090 FOR PREPARING PHARMACEUTICAL COMPOSITION FOR REGULATING IMMUNITY DAVIS, RUTH A 1699 Other Non-Final OA 78d overdue Pending Aug 01, 2024
17862766 COMPOSITION WITH LACTOBACILLUS PARACASEI AND A METHOD TO TREAT NASOPHARYNGEAL CARCINOMA THROUGH PYROPTOSIS OR CELL CYCLE ARREST DURYEE, ALEXANDER MARSH 1657 §103 Final Rejection 37d overdue Pending Jul 12, 2022

Managing Genmont Biotech Incorporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month